Awareness Programs, Restructuring Efforts, Conference Calls, Marketing Authorization Withdrawal and Clinical Trial Commencement - Research Report on Lilly, Teva, Elan, Zoetis, and Boston Scientific

Editor Note: For more information about this release, please scroll to bottom.

News provided by

Oct 16, 2013, 08:00 ET

NEW YORK, October 16, 2013 /PRNewswire/ --

Today, Analysts' Corner announced new research reports highlighting Eli Lilly & Co. (NYSE: LLY), Teva Pharmaceutical Industries Ltd. (ADR) (NYSE: TEVA), Elan Corporation, plc (NYSE: ELN), Zoetis Inc. (NYSE: ZTS) and Boston Scientific Corporation (NYSE: BSX). Today's readers may access these reports free of charge - including full price targets, industry analysis and analyst ratings - via the links below.

Eli Lilly & Co. Research Report

On October 11, 2013, Lilly Diabetes, a business unit of Eli Lilly & Co. (Lilly), announced that it is supporting NASCAR driver, Ryan Reed and American Diabetes Association (the Association) on Drive to Stop Diabetes^[^SM^], a national diabetes awareness initiative. Lilly Diabetes said that it will help sponsor Reed's car, the No. 16 American Diabetes Association Drive to Stop Diabetes^[^SM^] Ford Mustang, for the remainder of the 2013 and all of the 2014 racing seasons. The Company stated that Reed has competed in several Nationwide Series races for Roush Fenway Racing in 2013 and will continue throughout the 2014 season. According to the Company, through his non-profit organization called Ryan's Mission, Reed, a type 1 diabetes patient has collaborated with the Association on the Drive to Stop Diabetes^[^SM^] initiative, to help bring awareness and diabetes education to thousands of spectators at select NASCAR races nationwide, as well as several off-track health and wellness initiatives. The Full Research Report on Eli Lilly & Co. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.analystscorner.com/r/full_research_report/977d_LLY]

Teva Pharmaceutical Industries Ltd. (ADR) Research Report

On October 10, 2013, Teva Pharmaceutical Industries Ltd. (Teva) announced steps to reduce costs and to optimize its structure and processes, as part of the Company's worldwide restructuring program, introduced in December 2012. The Company stated that it will reduce its global workforce by approximately 10% (approximately 5,000 employees), a major part of which is likely to be complete by the end of 2014. Teva added that it continues to identify opportunities to optimize value through the selective trimming of assets that no longer fit its core business or are not critical to its future. Lastly, Teva informed that it intends to scale down oversized parts of the Company, while growing its generics business and core R&D programs (including high-value complex generics), expanding its presence in emerging markets and broadening its portfolio, especially in its specialty medicines and over-the-counter businesses. The Full Research Report on Teva Pharmaceutical Industries Ltd. (ADR) - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.analystscorner.com/r/full_research_report/e3a3_TEVA]

Elan Corporation, plc Research Report

On October 10, 2013, Elan Corporation, plc (Elan) announced that it will release Q3 2013 results on Thursday, October 24, 2013 before the European and U.S. financial markets open. The Company informed that it will host a conference call on the same day at 8:30 a.m. Eastern Time (ET), 1:30 p.m. British Summer Time (BST) to discuss the Company's quarterly results. The Full Research Report on Elan Corporation, plc - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.analystscorner.com/r/full_research_report/e996_ELN]

Zoetis Inc. Research Report

On October 1, 2013, Zoetis Inc. (Zoetis) announced that it has notified the U.S. Food and Drug Administration (FDA) that the Company will voluntarily withdraw the marketing authorizations (New Animal Drug Applications) for 3-Nitro (roxarsone) and Carb-O-Sep (carbarsone). The Company stated that it has decided to withdraw the marketing rights for 3-Nitro, a feed medicine containing organic arsenical roxarsone, after the suspension of U.S. sales of this product on July 8, 2011. According to Zoetis, the Company has suspended sales of the product at the request of the FDA, based on a study conducted by the Agency. The Company stated that it no longer manufactures 3-Nitro and has decided to withdraw the marketing authorization for this product. In addition, Zoetis stated that Carb-O-Sep, another arsenical feed medicine, has not been manufactured or marketed for a decade, and hence the Company has decided to withdraw marketing authorization for this product. The Full Research Report on Zoetis Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.analystscorner.com/r/full_research_report/7e25_ZTS]

Boston Scientific Corporation Research Report

On October 9, 2013, Boston Scientific Corporation (Boston Scientific) announced that it has commenced clinical trial of Innovaâ"¢ Peripheral Vascular Drug-Eluting Stent System. According to the Company, a physician in Auckland, New Zealand, has performed the first patient implant of Innova ™ Drug-Eluting Stent (DES) System, marking the beginning of a key clinical trial that is expected to serve as the foundation for global regulatory approvals. The Company stated that the MAJESTIC TRIAL which is designed to evaluate the safety and performance of the Boston Scientific peripheral drug-eluting stent system is expected to enroll 55 patients across 15 centers in Europe, Australia, and New Zealand. Jeff Mirviss, President, Peripheral Interventions, Boston Scientific, said, "Millions of patients around the world suffer the debilitating effects of peripheral artery disease (PAD), including amputation and an elevated risk for major cardiovascular events. The Innova DES System builds upon the Boston Scientific leadership in both peripheral vascular devices and drug-eluting technologies, and we look forward to bringing this meaningful innovation forward to improve outcomes for patients with PAD." The Full Research Report on Boston Scientific Corporation - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.analystscorner.com/r/full_research_report/5640_BSX]

----

EDITOR NOTES:

This is not company news. We are an independent source and our views do not reflect the companies mentioned.
Information in this release is fact checked and produced on a best efforts basis and reviewed by Namrata Maheshwari, a CFA charterholder. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.
This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.
If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at [email protected].
For any urgent concerns or inquiries, please contact us at [email protected].
Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to [email protected] for consideration.

COMPLIANCE PROCEDURE

Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Equity News Network. An outsourced research services provider represented by Namrata Maheshwari, CFA, has only reviewed the information provided by Equity News Network in this article or report according to the Procedures outlined by Equity News Network. Equity News Network is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.

NOT FINANCIAL ADVICE

Equity News Network makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED

Equity News Network is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Equity News Network whatsoever for any direct, indirect or consequential loss arising from the use of this document. Equity News Network expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Equity News Network does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

AnalystsCorner.com

SOURCE Analysts' Corner